AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Company Overview

A Purposeful, Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious disease of the microbiome.

Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.

To combat the rapidly growing global problem of multidrug-resistant bacterial infections, Armata is utilizing two proprietary platforms – synthetic bacteriophage (phage) and peptides.

Armata is headquartered in Marina del Rey, California, in a 35,000 square foot facility built for product development with capabilities spanning bench to clinic. Microbiologists, dedicated to the discovery of natural phages, are complemented by a team of scientists that harness the natural power and diversity of these phages through synthetic biology and engineering. In-house formulation development allows tailoring of the drug product to an indication, and Armata’s GMP drug manufacturing suites enable the production, purification, testing and release of clinical trial material. All of this is embedded in a seasoned team of professionals with extensive clinical development experience.